Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Z Gastroenterol. 2008 Dec;46(12):1369-71. doi: 10.1055/s-2008-1027411. Epub 2008 Dec 3.

Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH).

Author information

  • 1III. Department of Medicine, University Medical Center Hamburg. cschramm@uke.de

Abstract

The prevalence of non-alcoholic steatohepatitis (NASH) is increasing. NASH confers an increased risk of liver-related morbidity and mortality with a substantial risk of developing liver cirrhosis. At present, there is no established medical treatment for NASH. The pathogenesis of NASH is incompletely understood. Several lines of evidence suggest that TNF-alpha may be involved in the pathogenesis of NASH by promoting liver inflammation, insulin resistance and hepatocyte apoptosis. Anti-TNF-alpha therapy has not been evaluated for the treatment of NASH. We report here on a patient with NASH who has experienced rapid normalization of liver biochemistry during treatment of an associated rheumatoid arthritis with the humanized anti-TNF-alpha antibody adalimumab. This observation suggests that pilot studies may be warranted to evaluate the role of adalimumab for the treatment of NASH.

PMID:
19053005
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Georg Thieme Verlag Stuttgart, New York
    Loading ...
    Write to the Help Desk